他汀类药物对接受蒽环类药物治疗患者心脏毒性的减轻作用：一项系统评价和荟萃分析。

Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis.

作者信息

Titus Anoop, Cheema Huzaifa Ahmad, Shafiee Arman, Seighali Niloofar, Shahid Abia, Bhanushali Karan B, Kumar Ashish, Khan Safi U, Khadke Sumanth, Thavendiranathan Paaladinesh, Hundley W Gregory, Scherrer-Crosbie Marielle, Nohria Anju, Neilan Tomas G, Dani Sourbha S, Nasir Khurram, Ganatra Sarju

机构信息

Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA.

Department of Cardiology, King Edward Medical University, Lahore, Pakistan.

出版信息

Curr Probl Cardiol. 2023 Oct;48(10):101885. doi: 10.1016/j.cpcardiol.2023.101885. Epub 2023 Jun 17.

DOI:10.1016/j.cpcardiol.2023.101885

PMID:37336312

Abstract

Anthracycline chemotherapy causes cardiotoxicity, and the evidence regarding the benefit of concomitant statin use in reducing it remains uncertain. We conducted a meta-analysis of studies using statins and anthracyclines by searching PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from inception until April 10, 2023. Our analysis included 3 observational studies and 4 RCTs, including the STOP-CA trial released in ACC23. Statin prescription significantly reduced cardiotoxicity in cancer patients receiving anthracycline chemotherapy (OR 0.46, 95% CI: 0.33-0.63; I2: 0%). However, no significant difference was observed in the decline of left ventricular ejection fraction (LVEF) from baseline (MD 4.15, 95% CI: -0.69 to 8.99, I2: 97%). These findings demonstrate the protective effect of concomitant statin prescription.

摘要

蒽环类化疗药物会导致心脏毒性，而关于同时使用他汀类药物在降低其毒性方面的益处的证据仍不明确。我们通过检索PubMed、Embase、Cochrane图书馆和ClinicalTrials.gov，对从创建到2023年4月10日使用他汀类药物和蒽环类药物的研究进行了荟萃分析。我们的分析包括3项观察性研究和4项随机对照试验，其中包括在ACC23上发布的STOP-CA试验。他汀类药物处方显著降低了接受蒽环类化疗的癌症患者的心脏毒性（比值比0.46，95%置信区间：0.33-0.63；I²：0%）。然而，从基线开始左心室射血分数（LVEF）的下降没有观察到显著差异（平均差4.15，95%置信区间：-0.69至8.99，I²：97%）。这些发现证明了同时使用他汀类药物处方的保护作用。